Nafarelin in the treatment of pelvic pain caused by endometriosis.
As part of a large, multicenter trial, 82 patients with endometriosis were randomized to 6 months of treatment with either nafarelin or danazol. Among 73 patients who had subjective symptoms (dysmenorrhea, dyspareunia, or pelvic pain) at baseline, 94% of patients treated with nafarelin and 91% of those treated with danazol had improvement. Resolution of physical findings also was observed in similar percentages of patients in each treatment group. Long-term studies are needed to determine whether these two agents are associated with different cure rates or times to recurrence of disease.
Shaw
R W
RW
Academic Department of Obstetrics and Gynecology, Royal Free Hospital School of Medicine, London, United Kingdom.
D000568:Amenorrhea / Q000139:chemically induced; D002986:Clinical Trials as Topic; D003613:Danazol / Q000627:therapeutic use; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D017274:Nafarelin; D010146:Pain / Q000188:drug therapy / Q000209:etiology
D017274:Nafarelin; D007987:Gonadotropin-Releasing Hormone; D003613:Danazol